Treatment of Autoimmune Hemolytic Anemia

Initial Treatment Approach

The American College of Physicians recommends corticosteroids as the first-line treatment for autoimmune hemolytic anemia caused by antibodies that destroy red blood cells, with prednisone 1-2 mg/kg/day recommended for warm antibody AIHA 1, 2
For warm autoimmune hemolytic anemia, corticosteroids are the first-line treatment with an expected response rate of 70-80% 2
Recommended dosing for moderate AIHA is oral prednisone 0.5-1 mg/kg/day, and for severe AIHA, intravenous methylprednisolone 1-2 mg/kg/day 2
Folic acid supplementation of 1 mg daily should be administered to support increased erythropoiesis 2
Hemoglobin levels should be monitored weekly until steroid tapering is complete 2

For hemolytic anemia not responding to first-line therapy, consider immunosuppressive agents such as cyclosporine, mycophenolate mofetil, or azathioprine 2

In CLL-associated AIHA, autoimmune cytopenia not responding to conventional autoimmune therapy is an indication for CLL treatment 1, 3
Patients on long-term steroids should be monitored for steroid-related complications, including hyperglycemia, hypertension, mood changes, insomnia, and fluid retention 2

Direct antiglobulin test (DAT/Coombs test) should be performed before initiating treatment 4
Evaluate hemolysis markers including LDH, haptoglobin, bilirubin, and reticulocyte count 2, 4
Peripheral blood smear should be examined for evidence of hemolysis 4
Common drug causes of AIHA include ribavirin, rifampin, dapsone, interferon, cephalosporins, penicillins, NSAIDs, and fludarabine 4
In patients with immune checkpoint inhibitor therapy, hemolytic anemia may occur as an immune-related adverse event 5

Delaying treatment in severe cases can increase morbidity and mortality 2
IV anti-D should be used with caution as it can exacerbate hemolysis in patients with AIHA 2
Repeated testing may be necessary if initial results are negative but clinical suspicion remains high 4
Incomplete removal of platelets and leukocytes can lead to false-normal enzyme activity levels in diagnostic testing 4

Cold agglutinins or cryoglobulins may affect IgM level determination, which is crucial in diagnosing warm AIHA, according to the National Comprehensive Cancer Network 6

The American Society of Hematology recommends rituximab as a second-line treatment for steroid-refractory or relapsed warm AIHA cases, with a response rate of 60-80% and potential for long-lasting complete remission 6